<DOC>
	<DOCNO>NCT00807313</DOCNO>
	<brief_summary>Patients oligometastatic colorectal cancer ( 5 metastasis less ) receive combination systemic treatment often local treatment , surgery , radiofrequency ablation recently stereotactic body radiotherapy . The aim study register result side effect stereotactic body radiotherapy ( SBRT ) mean helical tomotherapy treatment oligometastatic colorectal cancer . The trial two cohort . Patients cohort I get consolidation SBRT best response first line chemotherapy . Patients cohort II get SBRT progression , indication ( ) chemotherapy . The primary endpoint evaluate metabolic complete remission rate three month start radiotherapy .</brief_summary>
	<brief_title>Non-interventional Observational Study Helical Tomotherapy Oligometastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Patients ( residual ) oligometastatic CRC : ≤ 5 mets Primary tumor treat curative intention ( surgery , radiotherapy , chemoradiotherapy ) Functional liver volume &gt; 1000cc livermets , lung DLCO &gt; 30 % lungmets . No Child B C liver cirrhosis No contraindication radiation metastatic CRC ( = violation constraint organ risk ( OAR ) ) No mets another carcinoma Age &gt; 18 year WHOPS ≤ 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Oligometastatic disease</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Stereotactic body radiotherapy</keyword>
	<keyword>Tomotherapy</keyword>
	<keyword>Metabolic response</keyword>
	<keyword>Stage IV</keyword>
</DOC>